Cymabay Therapeutics, Inc.CBAY was a big mover last session, as its shares rose over 6% on the day. The move came after the company announced positive interim results from its ongoing low-dose Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a life-threatening and life-limiting chronic cholestatic liver disease.
This led too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up almost 45% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.
Cymabay Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%
CymaBay Therapeutics Inc. Price
CymaBay Therapeutics Inc. Price | CymaBay Therapeutics Inc. Quote
A better-ranked stock in the broader sector is Anthem, Inc. ANTM , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CymaBay Therapeutics Inc. (CBAY): Free Stock Analysis Report
Anthem, Inc. (ANTM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
